Population Pharmacokinetic/Pharmacodynamic Modeling of the Effect of Abrocitinib on QT Intervals in Healthy Volunteers
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1111
Abstract: Abrocitinib is a selective Janus kinase 1 inhibitor for the treatment of moderate to severe atopic dermatitis (AD). To assess the relationship between abrocitinib plasma concentrations and heart rate (HR)–corrected QT (QTc) and HR and… read more here.
Keywords: effect abrocitinib; healthy volunteers; effect; population pharmacokinetic ... See more keywords
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-020-04204-y
Abstract: This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) treated in the phase 3… read more here.
Keywords: relapsed refractory; qtcf; analysis; quizartinib ... See more keywords
Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac372
Abstract: Abstract Background The M2 metabolite of bedaquiline causes QT-interval prolongation, making electrocardiogram (ECG) monitoring of patients receiving bedaquiline for drug-resistant tuberculosis necessary. The objective of this study was to determine the relationship between M2 exposure… read more here.
Keywords: ecg monitoring; qtcf; monitoring strategies; monitoring ... See more keywords
Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumors: a concentration-QT analysis.
Sign Up to like & getrecommendations! Published in 2023 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15700
Abstract: AIM Patients with solid tumors were treated with the anti-PD-1 antibody dostarlimab in the Phase I GARNET trial. This study aimed to examine dostarlimab's effect on corrected QT (QTc) interval and the systemic concentration-QTc interval… read more here.
Keywords: patients solid; prolongation; dostarlimab; concentration ... See more keywords